1. Home
  2. ZYME

ZYME

Zymeworks Inc.

Logo Zymeworks Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 3:32pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Founded: 2003 Country:
Canada
Canada
Employees: N/A City: MIDDLETOWN
Market Cap: 660.5M IPO Year: 2017
Target Price: $15.25 AVG Volume (30 days): 574.3K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.72 EPS Growth: N/A
52 Week Low/High: $6.02 - $13.14 Next Earning Date: 05-06-2024
Revenue: $76,012,000 Revenue Growth: -81.57%
Revenue Growth (this year): 64.8% Revenue Growth (next year): -22.61%

Share on Social Networks: